Gegenanzeigen · Qdenga
Qdenga powder and solvent for solution for injection Qdenga powder and solvent for solution for injection in pre-filled syringe Dengue tetravalent vaccine (live, attenuated) · Abschnitt 4.3 · PDF-Seite 3
HOS-144692 · Präparat HOS-099244
• Individuals with congenital or acquired immune deficiency, including those receiving immunosuppressive therapies such as high doses of systemic corticosteroids (e.g. 20 mg/day or 2 mg/kg body weight/day of prednisone for 2 weeks or more) within 4 weeks prior to vaccination, or any other medicinal product with known immunosuppressive properties including chemotherapy. The time to avoid vaccination after immunosuppressive treatment should be considered on an individual basis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-04T12:15:00Z · SHA-256 f0e1da92d206a9ab00b8eab81d75d970f8b633f9b7c5ab9ec49d461a2b3745c5 · Passage 1107e334a7cf06a007557d5df000505cafae5eea05e09c0dabbd6e2505ac42aa · Zeichen 165–703 im Abschnitt